Janssen Biotech Inc. hopes it will be first to market with a drug for non-metastatic castration-resistant prostate cancer (CRPC) with the submission of its next-generation androgen receptor inhibitor apalutamide, based on a Phase III study providing data on metastasis-free survival.
Apalutamide will be positioned in tandem with Janssen’s blockbuster prostate cancer therapy Zytiga (abiraterone acetate). "Prostate cancer is an area...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

